Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs

Epilepsy Research

Volumn 95, Issue 1-2, 2011, Pages 158-167

  Bautista, Ramon Edmundo D ^a   Gonzales, Walter ^a   Jain, Deepali ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

Adverse drug effects; Antiepileptic drugs; Beliefs About Medicines Questionnaire; Epilepsy; Generic AEDs; Seizure frequency

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; AFRICAN AMERICAN; ARTICLE; BELIEFS ABOUT MEDICINES GENERAL QUESTIONNAIRE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CONTROL; DIZZINESS; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG UTILIZATION; EDUCATIONAL STATUS; EPILEPSY; FEMALE; HEALTH SURVEY; HUMAN; INSURANCE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MOTOR VEHICLE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SEIZURE;

ADULT; ANTICONVULSANTS; CONTINENTAL POPULATION GROUPS; CULTURE; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; QUESTIONNAIRES; REGRESSION ANALYSIS; RISK FACTORS; SEIZURES; SOCIOECONOMIC FACTORS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 79957930124     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.03.014     Document Type: Article

References (25)

1. Andermann F., Duh M.S., Gosselin A., Paradis P.E. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007, 48:464-469.
2. Berg M.J., Gross R.A., Tomaszewski K.J., Zingaro W.M., Haskins L.S. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008, 71:2525-2530.
3. Berg M.L., Gross R.A., Haskins L.S., Zingaro W.M., Tomaszewski K.J. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 2008, 13:693-699.
4. Brown E., Shellhorn E., Suppes T. Gastrointestinal side effects after switch to generic valproate. Pharmacopsychiatry 1998, 31:114.
5. Cramer J.A., Perrine K., Devinsky O., Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 1996, 37:577-582.
6. Crawford P., Hall W.W., Chappell B., Collings J., Stewart A. Generic prescribing for epilepsy. Is it safe?. Seizure 1995, 5:1-5.
7. Gilliam F.G., Barry J.J., Hermann B.P., Meador K.J., Vahle V., Kanner A.M. Rapid detection of major depression in epilepsy: a multicenter study. Lancet Neurol. 2006, 5:399-405.
8. Gilman J.T., Alvarez L.A., Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993, 42:2696-2697.
9. Hartley R., Aleksandrowicz J., Bowmer C.J., Cawood A., Forsythe W.I. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. J. Pharm. Pharmacol. 1991, 43:117-119.
10. Helmers S.L., Paradis P.E., Manjunath R., Duh M.S., Lafeuille M.H., Latrémouille-Viau D., Lefebvre P., Labiner D.M. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav. 2010, 18:437-444.
11. Hodges S., Forsythe W.I., Gillies D., Remington H., Cawood A. Bio-availability and dissolution of three phenytoin preparations for children. Dev. Med. Child Neurol. 1986, 28:708-712.
12. Horne R., Weinman J., Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol. Health 1999, 14:1-24.
13. Horne R., Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 1999, 47:555-567.
14. Kishore K., Jailakhani B.L., Sharma J.N., Ahuja G.K. Serum phenytoin levels with different brands. Indian J. Physiol. Pharmacol. 1986, 30:171-176.
15. Kramer G., Biraben A., Carreno M., Guekht A., de Haan G.J., Jedrzejczak J., Josephs D., van Rijckevorsel K., Zaccara G. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav. 2007, 11:46-52.
16. Labiner D.M., Paradis P.E., Manjunath R., Duh M.S., Lafeuille M.H., Latrémouille-Viau D., Lefebvre P., Labiner D.M. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010, 74:1566-1574.
17. LeLorier J., Duh M.S., Paradis P.E., Lefebvre P., Weiner J., Manjunath R., Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008, 70:2179-2186.
18. McAuley J.W., Chen A.Y., Elliott J.O., Shneker B.F. An assessment of patient and pharmacist knowledge of and attitudes towards reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav. 2009, 14:113-117.
19. Oles K.S., Penry J.K., Smith L.D., Anderson R.L., Dean J.C., Riela A.R. Therapeutic bioequivalence study of brand name versus generic carbamazepine. Neurology 1992, 42:1147-1153.
20. Papsdorf T.B., Ablah E., Ram S., Sadler T., Liow K. Patient perception of generic drugs in the Midwestern United States. Epilepsy Behav. 2009, 14:150-153.
21. Sipalkit O., Amornpichetkoon M., Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann. Pharmacother. 1997, 31:548-552.
22. Soryal I., Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J. Neurol. Neurosurg. Psychiatry 1992, 55:688-691.
23. Vandney V.J., Kraushaar K.W. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment. Retard. 1997, 35:468-472.
24. Welty T.E., Pickering P.R., Hale B.C., Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann. Pharmacother. 1992, 26:775-777.
25. Wolf P., May T., Tiska G., Schreiber G. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimittelforschung 1992, 42:284-288.